GSK_Annual_Report_2021

Notes to the Standalone Financial Statements for the year ended March 31, 2021 (contd.) Financial Statements GlaxoSmithKline Pharmaceuticals Limited 142 GlaxoSmithKline S.A.E., Egypt* GlaxoSmithKline Inc, Philadelphia* GlaxoSmithKline Manufacturing SPA, Italy* GlaxoSmithKline Intellectual Property Limited* GlaxoSmithKline (Thailand) Ltd. * no transactions during the year (iv) Directors and members of GSK India Leadership Team : Directors: GSK India Leadership Team: Ms. P. Thakur # Mr. A. Nadkarni Mr. S. Venkatesh # (w.e.f. April 1, 2020) Mr. R. D'souza Mr. M. Dawson (w.e.f. Janaury 28, 2021) Mr. S. Dheri Ms. S.Maheshwari (w.e.f. May 18, 2020) Ms. S. Choudhary Mr. N. Kaviratne Mr. B. Kotak Mr. P. Bhide Mr. A. Iyer Ms. R. S. Karnad Mr. S. Balasubramanian Mr. A. N. Roy Mr. A. Kashyap (w.e.f. May 28, 2020) Mr. D. Sundaram Mr. B. Akshikar (w.e.f. December 1, 2020) Mr. S. Williams Mr. C. Sharma (w.e.f. December 1, 2020) Mr. R. Krishnaswamy # (upto January 27, 2021) Mr. N. Hindia (w.e.f. June 1, 2018 upto March 22, 2020 and w.e.f. January 4, 2021) Ms. A. Bansal (upto March 29, 2020) Ms. M. Priyam (upto August 31, 2020) Mr. A. Vaidheesh # (upto March 31, 2020) Ms. D. Jakate (upto January 31, 2021) Ms. S. Zota (w.e.f. March 23, 2020 upto December 31, 2020) Mr. G. Kotian (w.e.f. October 1, 2018 upto October 31, 2019) Mr. N. Sudrik (w.e.f. October 1, 2018 upto October 31, 2019) Ms. S. Ghosh(w.e.f. August 25, 2020 upto December 1, 2020) # Also member of GSK India Leadership Team 2 The following transactions were carried out with the related parties in the ordinary course of business: (i) Dividend paid to parties referred to in item 1(i) above: ( ` in lakhs) Year ended March 31, 2021 Year ended March 31, 2020 Glaxo Group Limited, U.K. 219,49.38 121,94.10 GlaxoSmithKline Pte Limited, Singapore 171,37.45 95,20.80 Eskaylab Limited, U.K. 42,33.60 23,52.00 Burroughs Wellcome International Limited, U.K. 24,19.20 13,44.00